EcoDrugPlus

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSORLG00000012708
Gene Symbol: LYN
4 Cross references
195 Possible Orthologues:

Malt Paracaspase 1

Ensembl ID : ENSORLG00000000330
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSORLG00000015745
Gene Symbol: MAPKAPK2
4 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSORLG00000003628
Gene Symbol: MAPKAPK5
4 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSORLG00000009024
Gene Symbol: MKNK2B
4 Cross references
208 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSORLG00000015753
Gene Symbol: MCL1B
4 Cross references
211 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSORLG00000017163
Gene Symbol: MDM2
4 Cross references
275 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSORLG00000019737
Gene Symbol: MET
4 Cross references
205 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog (S. Cerevisiae)

Ensembl ID : ENSORLG00000003112
Gene Symbol: MLST8
4 Cross references
198 Possible Orthologues:

N-Acetylated Alpha-Linked Acidic Dipeptidase 2

Ensembl ID : ENSORLG00000011078
Gene Symbol: NAALAD2
4 Cross references
337 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSORLG00000012854
Gene Symbol: NPC1L1
4 Cross references
189 Possible Orthologues:

Nt-3 Growth Factor Receptor

Ensembl ID : ENSORLG00000018691
Gene Symbol: LOC101168685
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).